Health Restructuring for Efficiency and Controlled Costs |

Healthcare is at the center of attention on an international scale, on the one hand due to the coronavirus pandemic and on the other hand due to the revolution caused by new technologies, artificial intelligence and their applications in medical science and care.

However, health systems around the world are also facing staff shortages – Europe alone is short of one million health workers, with shortage pressures suffocating as the population ages.

Accordingly, our lack of employees has led to unprecedented recruitments, which exceed 5.5 to 6 thousand this year, and 6.5 thousand are already planned for 2024.

“Our hospitals are currently flooded with new technologies”

The Minister of Health mentioned above Michalis Chrysochoidis at the 27th Economist conference, which again emphasized the position of restarting the healthcare system to make it more flexible and attractive, adapted to the aging population, despite the fact that we have an excellent scientific potential, a large part of which has gone abroad.

The minister spoke about a new way of organizing hospitals with predetermined budgets and rational management, similar to European management standards, with tenders and competition. Significantly, he said that when the government mandates the rules of healthy competition, then everything works very well both in the market and in health. Where the rules are not followed, competition is distorted.

He referred to the universal application by March DRG to have data on hospitalizations, expenses, costs, digitization and grouping and competitions as a whole through EKAPY on the supply of materials and the functioning of the competition.

He emphasized the creation of three new hospitals through St. Niarchos in Komotini, the Pediatric Hospital of Thessaloniki and the Hospital of Sparta, while the construction procedures of the Oncology Hospital in Thessaloniki are accelerating.

At the same time, through the Recovery Fund and NSRR, “our hospitals are currently overwhelmed with new technologies”, with new facilities for anti-cancer treatment being created. The revolution, he said, will occur after a year and a half with the digital health map.

He also announced the operation of EOPYY as an insurance company, and with the advent of digitization for health, there will be real-time audits and rationalization of costs.


Restructuring includes both EOF and policy medicine.

Here, Mr. Chrysochoidis said that while spending is increasing every year, “we are not going to deprive ourselves of any but any innovative new pharmaceutical action that enters the country.” However, he emphasized that efficiency and cost criteria should be met.

At the same time, he did not fail to mention that the intention is to further support the investments of the Greek pharmaceutical industry, which has seen very significant jumps in recent years. “We support it with investment and incentives, we support it with reinvestment, we support it in many ways. And Greece was really lucky to have an extremely robust industry that exports a lot,” he concluded.

Greek pharmaceutical industry

On behalf of the Greek pharmaceutical industry at a special round table at the same conference, its president Panhellenic Pharmaceutical Industry Association Theodoros Tryfon emphasized that “The new European pharmaceutical policy is a unique opportunity for our country, as it provides incentives for investments aimed at strengthening the production of medicines in Europe. Greece has a strong manufacturing base as Greek factories represent 12% of the EU’s total manufacturing potential”.

EOPYY Director Theano Karpodini and Head of the Special Coordination Service of the Reconstruction Fund Orestis Kavalakis took part in the discussion.

At the center of the discussion was the competitiveness of the pharmaceutical industry at the pan-European and local level, the importance of ensuring pharmaceutical coverage for all patients, as well as the priorities of our country in terms of the development of the domestic pharmaceutical industry sector. .

PEF President Th.Tryfon emphasized that “our country should take advantage of the existence of domestic pharmaceutical production, a sector that invests, operates with extroversion and produces internationally tradable products that add value to the Greek economy and society”.

Mr. Tryfon specifically mentioned the investments made by the Greek pharmaceutical industry in the context of the important stimulus provided by the government through the recovery fund, stressing that “it is a 1.2 billion euro investment program to modernize existing production facilities”. and research infrastructures, as well as the creation of new ones. These investments will create significant added value for the economy, boost employment and further improve patient coverage.”

Referring to the challenges for the sector, Mr. Tryfon pointed out that “the most serious threat to the completion of the investment program is excessive direct and indirect taxation of the sector. As he pointed out, “this enormous burden not only creates marginal conditions of viability for hundreds of drugs, but also deprives them of valuable development funds.” The President of PEF emphasized that the reduction of excessive taxation will unlock even greater investments by the pharmaceutical industry and further increase its competitiveness.

The Greek pharmaceutical industry has stood by the Greek patient and Greek society for 90 years, building a unique relationship with deep roots. Our investments ensure the adequacy of the domestic pharmaceutical market and bring Greece to the center of the European pharmaceutical scene.

Leave a Reply

Your email address will not be published. Required fields are marked *